Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: I wonder if PTSC was required to notIfy shareholders and/or SEC of the Summary Judgment.

No need to beat yourself up at this juncture.  We are where we are.

Nevertheless, when I see people asking the "Who's doing all the buying?" question in a company like PTSC, it concerns me.  Nothing personal toward EA, but, generally speaking, such inquiries are IMO either disingenuous or unmindful of the circumstances.

What anyone considering a purchase of PTSC stock should be doing at this juncture is making an objective evaluation of what the Company has to offer.  Merely because others are buying is all but irrelevant.  For one thing, 1.7 million shares @ .004 = about $6800.00, which isn't very much in terms of the millions of potential investors around the world.  Then, we have the "lemming factor".  Instead, important questions would be among the following.

Does the Company have any products or services to sell?  Nope, not that I know of.

Does it have valuable and enforceable patents?  Nope, the patents have expired, and the "lookback" doesn't appear to offer much promise.

Does it have management who has been "shareholder friendly", or at least effective in maintaining shareholder value?  Nope, not as I see it   ---   the stock price has plunged some 99% over the last decade, management has been virtually incommunicado over the last five years or so, and at least one of them has recently been ousted as a board member in another public company.

I could go on, but you get the gist.  Instead of merely asking who is buying, the important question is what PTSC currently has to offer that would justify buying. 

 

Share
New Message
Please login to post a reply